Hsbc Holdings PLC Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Hsbc Holdings PLC purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, Holdings Channel reports. The institutional investor purchased 413,195 shares of the medical equipment provider’s stock, valued at approximately $35,417,000.

Other institutional investors have also recently made changes to their positions in the company. EFG International AG bought a new stake in shares of Zimmer Biomet in the second quarter valued at about $53,000. Ancora Advisors LLC purchased a new position in Zimmer Biomet during the 2nd quarter valued at about $29,000. Primecap Management Co. CA purchased a new position in Zimmer Biomet during the 2nd quarter valued at about $328,578,000. Canada Pension Plan Investment Board bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at about $32,543,000. Finally, Parkman Healthcare Partners LLC bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at about $20,021,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 2.0%

NYSE:ZBH opened at $99.40 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $106.88. The firm has a 50 day moving average of $93.63 and a 200 day moving average of $91.38. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $18.96 billion, a price-to-earnings ratio of 24.19, a PEG ratio of 2.76 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the firm earned $2.07 earnings per share. Zimmer Biomet’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of recent research reports. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Citigroup reduced their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a report on Thursday, August 6th. Royal Bank Of Canada increased their target price on Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Finally, UBS Group reiterated a “buy” rating and issued a $120.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $104.42.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.